Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine

Erguven,Mine; Bilir,Ayhan; Yazihan,Nuray; Korkmaz,Seval; Aktas,Esin; Ovalioglu,Cem; Dundar,Tolga; Seyithanoglu,Hakan

doi:10.3892/ol.2011.434

Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine

Authors:
- Mine Erguven
- Ayhan Bilir
- Nuray Yazihan
- Seval Korkmaz
- Esin Aktas
- Cem Ovalioglu
- Tolga Dundar
- Hakan Seyithanoglu
View Affiliations

Affiliations: Yeni Yüzyıl University, Faculty of Medicine Department of Clinical Biochemistry, 34093 Cevizlibag-Topkapi, Istanbul, Turkey, Department of Histology and Embryology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, Faculty of Medicine, Department of Pathophysiology, Ankara University, Ankara, Turkey, Cell Culture and In Vitro Screening Laboratory, Abdi İbrahim Pharmaceuticals R__AMB__D Center, Istanbul, Turkey, Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey, Department of Neurosurgery, Bakırkoy Hospital, Istanbul, Turkey, Department of Neurosurgery, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey
Published online on: October 4, 2011 https://doi.org/10.3892/ol.2011.434
Pages: 200-208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to overcome resistance to imatinib (IM) by combining it with roscovitine (ROSC) and to investigate whether or not midkine (MK) had an effect on this combination in the treatment of glioblastoma (GBL). Human T98 GBL cells were used to evaluate the effects of IM (10 µM), ROSC (200 µM) and their combination on the cell proliferation index, apoptotic index, the apoptotic protein and anti-apoptotic protein levels, and ultrastructure. All applications decreased the cell proliferation index and increased the apoptotic index, but ROSC was the most efficient drug and the second most efficient drug was IM. Notably, ROSC increased anti‑apoptotic proteins levels (PDGFR-α, AQP-4, hTERT), COX-1 activity and ribosome numbers. The effects of ROSC on hTERT, MK, AQP-4 and MRP-1 levels and COX-1 activity were reported for the first time. ROSC induced the highest increase in caspase-3 levels. Autophagy was not involved in the activity of ROSC in GBL spheroids. The combination of IM with ROSC showed an antagonist effect in the treatment of human GBL cells. The combination group decreased certain anti‑apoptotic protein levels (PDGFR-α, EGFR, p-gp, MRP-1 and MK), cAMP levels, COX-1 activity and apoptotic protein levels (caspase-3). However, it induced the highest increase in hTERT levels and COX-2 activity. Ribosome numbers were much lower than those in the ROSC group and no autophagic vacuole was observed. In conclusion, more investigations are required to identify the key regulatory components that are responsible for this antagonism; however, the determination of this combination therapy as a failure therapy may be precautionary for oncologists in the treatment of GBL patients and potentially may contribute to the efficacy of new therapeutic regimens.

View Figures

View References

1	Krystof V and Uldrijan S: Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets. 11:291–302. 2010. View Article : Google Scholar : PubMed/NCBI
2	Aldoss IT, Tashi T and Ganti AK: Seliciclib in malignancies. Expert Opin Investig Drugs. 18:1957–1965. 2009. View Article : Google Scholar
3	Burger K, Mühl B, Harasim T, et al: Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem. 285:12416–12425. 2010. View Article : Google Scholar : PubMed/NCBI
4	Bach S, Knockaert M, Reinhardt J, et al: Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem. 280:31208–31219. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kim EH, Kim SU, Shin DY, et al: Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene. 23:446–456. 2004. View Article : Google Scholar : PubMed/NCBI
6	Komina O, Nosske E, Maurer M, et al: Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. J Exp Ther Oncol. 9:27–35. 2011.PubMed/NCBI
7	Dey A, Wong ET, Cheok CF, et al: R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis:implications in cancer therapy. Cell Death Differ. 15:263–273. 2008. View Article : Google Scholar : PubMed/NCBI
8	Maggiorella L, Aubel C, Haton C, et al: Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Prolif. 42:38–48. 2009. View Article : Google Scholar
9	Ganapathi SB, Kester M and Elmslie KS: State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol. 296:C701–C710. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yang SY, Miah A, Pabari A, et al: Growth Factors and their receptors in cancer metastases. Front Biosci. 16:531–538. 2011. View Article : Google Scholar : PubMed/NCBI
11	Natoli C, Perrucci B, Perrotti F, et al: Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Tyrosine kinase inhibitors. Curr Cancer Drug Targets. 10:462–483. 2010.PubMed/NCBI
12	Waller CF: Imatinib mesylate. Recent Results Cancer Res. 184:3–20. 2010. View Article : Google Scholar : PubMed/NCBI
13	Razis E, Selviaridis P, Labropoulos S, et al: Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 15:6258–6266. 2009. View Article : Google Scholar : PubMed/NCBI
14	Erguven M, Yazihan N, Aktas E, et al: Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol. 36:857–866. 2010. View Article : Google Scholar : PubMed/NCBI
15	Mangiola A, Anile C, Pompucci A, et al: Glioblastoma therapy: going beyond Hercules Columns. Expert Rev Neurother. 10:507–514. 2010. View Article : Google Scholar : PubMed/NCBI
16	Declèves X, Bihorel S, Debray M, et al: ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res. 57:214–222. 2008.PubMed/NCBI
17	Bihorel S, Camenisch G, Lemaire M, et al: Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem. 102:1749–1757. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ozawa T, Brennan CW, Wang L, et al: PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 24:2205–2218. 2010. View Article : Google Scholar : PubMed/NCBI
19	Muramatsu T: Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation. Int J Dev Biol. 37:183–188. 1993.PubMed/NCBI
20	Garver RI, Chan CS and Milner PG: Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol. 9:463–466. 1993. View Article : Google Scholar : PubMed/NCBI
21	Garver RI, Radford DM, Donis-Keller H, et al: Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 74:1584–1590. 1994. View Article : Google Scholar : PubMed/NCBI
22	Konishi N, Nakamura M, Nakaoka S, et al: Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 57:253–257. 1999. View Article : Google Scholar : PubMed/NCBI
23	Mishima K, Asai A, Kadomatsu K, et al: Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett. 233:29–32. 1997. View Article : Google Scholar : PubMed/NCBI
24	Torres KE, Castillo G and Horwitz SB: Proc Am Assoc Cancer Res. 38:5301997.
25	Fan W, Miller MC, Cheng RL, et al: Induction of apoptosis by low concentrations of Taxol is not dependent on a G2/M block. Microsc Microanal. 4:1042–1043. 1998.
26	Miller MC III, Johnson KR, Willingham MC, et al: Apoptotic cell death induced by baccatin III, a precursor of Taxol, occurs without G2/M arrest. Cancer Chemother Pharmacol. 44:444–452. 1999. View Article : Google Scholar : PubMed/NCBI
27	Yakisich JS, Boethius J, Lindblom IO, et al: Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport. 10:2563–2567. 1999. View Article : Google Scholar : PubMed/NCBI
28	Fleming IN, Hogben M, Frame S, et al: Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res. 14:4326–4335. 2008. View Article : Google Scholar : PubMed/NCBI
29	Mohapatra S, Chu B, Wei S, et al: Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 63:8523–8530. 2003.PubMed/NCBI
30	Spiegl-Kreinecker S, Buchroithner J, Elbling L, et al: Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol. 57:27–36. 2002. View Article : Google Scholar
31	Ding T, Ma Y, Li W, et al: Role of aquaporin-4 in the regulation of migration and invasion of human glioma cells. Int J Oncol. 38:1521–1531. 2011.PubMed/NCBI
32	Ibraghimov-Beskrovnaya O: Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle. 6:776–779. 2007. View Article : Google Scholar : PubMed/NCBI
33	Shukla S, Acharya S, Rajput D, et al: Telomere-the twilight to immortality. J Assoc Physicians India. 58:553–560. 2010.PubMed/NCBI
34	Marian CO, Cho SK, McEllin BM, et al: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 16:154–163. 2010. View Article : Google Scholar
35	Uziel O, Fenig E, Nordenberg J, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 92:1881–1891. 2005. View Article : Google Scholar : PubMed/NCBI
36	Deville L, Hillion J, Pendino F, et al: hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. Mol Cancer Ther. 10:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
37	Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
38	Reardon DA, Quinn JA, Vredenburgh J, et al: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 103:329–38. 2005. View Article : Google Scholar : PubMed/NCBI
39	Du J, Wei N, Guan T, et al: Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages. Am J Physiol Cell Physiol. 297:C742–9. 2009.PubMed/NCBI
40	Vigneron C, Nuttinck F, Perreau C, et al: Effect of roscovitine, a cdk1 inhibitor, and of the presence of oocyte on bovine cumulus cell expansion and cyclooxygenase-2 expression. Mol Reprod Dev. 65:114–21. 2003. View Article : Google Scholar : PubMed/NCBI
41	Arunasree KM, Roy KR, Anilkumar K, et al: Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res. 32:855–864. 2008. View Article : Google Scholar : PubMed/NCBI
42	Lambert LA, Qiao N, Hunt KK, et al: Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 68:7966–7974. 2008. View Article : Google Scholar : PubMed/NCBI
43	Hu R, Yan Y, Li Q, et al: Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol. 92:105–110. 2010. View Article : Google Scholar : PubMed/NCBI
44	Kang HC, Kim IJ, Park JH, et al: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res. 10:272–284. 2004. View Article : Google Scholar : PubMed/NCBI
45	Bilir A, Erguven M, Yazihan N, et al: Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol. 100:385–395. 2010. View Article : Google Scholar : PubMed/NCBI
46	Dai LC, Shao JZ, Min LS, et al: Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription. World J Gastroenterol. 14:6249–6253. 2008. View Article : Google Scholar : PubMed/NCBI
47	Van Riggelen J, Yetil A and Felsher DW: MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 10:301–309. 2011.PubMed/NCBI
48	Dai MS, Arnold H, Sun XX, et al: Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 26:3332–3345. 2007. View Article : Google Scholar : PubMed/NCBI
49	Lohrum MA, Ludwig RL, Kubbutat MH, et al: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 3:577–587. 2003. View Article : Google Scholar : PubMed/NCBI
50	Zhang Y, Wolf GW, Bhat K, et al: Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 23:8902–8912. 2003. View Article : Google Scholar : PubMed/NCBI
51	Bhat KP, Itahana K, Jin A, et al: Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23:2402–2412. 2004. View Article : Google Scholar : PubMed/NCBI
52	Muller AW: Thermosynthesis as energy source for the RNA World: a model for the bioenergetics of the origin of life. Biosystems. 82:93–102. 2005.PubMed/NCBI